Overview
- Editors:
-
-
C. Mark Smales
-
Protein Science Group, Department of Biosciences, University of Kent, Canterbury, UK
-
David C. James
-
School of Engineering, University of Queensland, St. Lucia, Australia
Access this book
Other ways to access
Table of contents (35 protocols)
-
-
- John R. Birch, Yemi Onakunle
Pages 1-16
-
- Andrew G. Popplewell, Mukesh Sehdev, Mariangela Spitali, A. Neil C. Weir
Pages 17-30
-
- Sang Yup Lee, Jong Hyun Choi, Sang Jun Lee
Pages 31-41
-
-
- Lee J. Byrne, Kenneth J. O’Callaghan, Mick F. Tuite
Pages 51-64
-
- Eric C. de Bruin, Erwin H. Duitman, Arjo L. de Boer, Marten Veenhuis, Ineke G. A. Bos, C. Erik Hack
Pages 65-76
-
- Zheng Jin, Si Lusheng, Wang Yili
Pages 77-86
-
- Sabine Geisse, Martin Jordan, Florian M. Wurm
Pages 87-98
-
- Bhaskar Thyagarajan, Michele P. Calos
Pages 99-106
-
- Lily Chu, Ilse Blumentals, Gargi Maheshwari
Pages 107-121
-
- Beat P. Kramer, Martin Fussenegger
Pages 123-143
-
- William P. Sheffield, Teresa R. McCurdy, Varsha Bhakta
Pages 145-154
-
-
- Surinder M. Singh, A. N. S. Eshwari, Lalit C. Garg, Amulya K. Panda
Pages 163-176
-
- Teruhisa Nakashima, Kazuhiko Tomokiyo
Pages 177-190
-
- Alberto L. Horenstein, Ilaria Durelli, Fabio Malavasi
Pages 191-208
-
- Nicola Boschetti, Anna Johnston
Pages 209-219
-
- Marina Korneyeva, Scott Rosenthal
Pages 221-231
-
- Aaron P. Miles, Daming Zhu, Allan Saul
Pages 233-242
About this book
With the recent completion of the sequencing of the human genome, it is widely anticipated that the number of potential new protein drugs and targets will escalate at an even greater rate than that observed in recent years. However, identification of a potential target is only part of the process in developing these new next generation protein-based “drugs” that are increasingly being used to treat human disease. Once a potential protein drug has been identified, the next rate-limiting step on the road to development is the production of sufficient authentic material for testing, charact- ization, clinical trials, and so on. If a protein drug does actually make it through this lengthy and costly process, methodology that allows the production of the protein on a scale large enough to meet demand must be implemented. Furthermore, large-scale production must not compromise the authenticity of the final product. It is also nec- sary to have robust methods for the purification, characterization, viral inactivation and continued testing of the authenticity of the final protein product and to be able to formulate it in a manner that retains both its biological activity and lends itself to easy administration. Therapeutic Proteins: Methods and Protocols covers all aspects of protein drug production downstream of the discovery stage. This volume contains contributions from leaders in the field of therapeutic protein expression, purification, characterization, f- mulation, and viral inactivation.
Reviews
"...scientists in the area will find the material of value." - Doody's Health Sciences Book Review Journal
Editors and Affiliations
-
Protein Science Group, Department of Biosciences, University of Kent, Canterbury, UK
C. Mark Smales
-
School of Engineering, University of Queensland, St. Lucia, Australia
David C. James